Press-release for stocks

Prices are updated after-hours

trial

save search

Innovent Announces First Patient Dosed with CD73 Antibody in Phase 1a/1b Clinical Trial for Advanced Solid Tumor
Published: 2022-02-23 (Crawled : 01:00) - biospace.com/
LLY | $745.95 -0.64% -0.1% 1.7M

Health Technology

| 213.96% | O: 0.59% H: 0.89% C: -0.93%
INCY | $52.82 0.19% 0.19% 1.8M

Health Technology

| -22.52% | O: 0.87% H: 0.84% C: -1.12%
cd73 trial phase 1 antibody phase 1b

Innovent Announces First Patient Dosed with CD73 Antibody in Phase 1a/1b Clinical Trial for Advanced Solid Tumor
Published: 2022-02-24 (Crawled : 01:00) - prnewswire.com
LLY | $745.95 -0.64% -0.1% 1.7M

Health Technology

| 215.04% | O: -1.4% H: 0.0% C: 0.0%
INCY | $52.82 0.19% 0.19% 1.8M

Health Technology

| -22.31% | O: -1.25% H: 1.21% C: 1.04%
cd73 trial phase 1 antibody phase 1b

Parker Scheduled to Present at the Evercore ISI Industrial Conference on February 28 at 9:40 a.m. Eastern Time
Published: 2022-02-23 (Crawled : 22:00) - globenewswire.com
PH | $538.09 -0.46% 0.0% 390K

Producer Manufacturing

| 86.45% | O: -2.24% H: 2.32% C: 2.03%
trial conference

Phase 4 PALADIN Study with ILUVIEN® Published in Peer-Reviewed Journal Ophthalmology
Published: 2022-02-23 (Crawled : 19:00) - biospace.com/
ALIM | $3.4 -4.23% -4.41% 57K

Health Technology

| -23.01% | O: -2.37% H: 5.43% C: 2.86%
iluvien

Horizon Therapeutics plc Initiates Phase 3 Clinical Trial (OPTIC-J) in Japan Evaluating Teprotumumab for the Treatment of Active Thyroid Eye Disease (TED)
Published: 2022-02-23 (Crawled : 19:00) - biospace.com/
HZNP | $116.3 0.03% 29M

Health Technology

| 25.38% | O: 0.97% H: 0.38% C: -2.35%
treatment eye eye disease trial therapeutics disease active phase 3

Ayala Pharmaceuticals Announces Completion of Enrollment in Part A of RINGSIDE, a Pivotal Phase 2/3 Study of AL102 in Desmoid TumorsInterim Results expected mid-2022
Published: 2022-02-23 (Crawled : 19:00) - biospace.com/
AYLA | $0.5036 5.84% -0.7% 0

Health Technology

| -88.61% | O: -4.52% H: 7.35% C: -4.98%
al102 phase 2 als phase 2/3 enroll

MyMD Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial of MYMD-1 as a Therapy for Delaying Aging and Extending Healthy Lifespan
Published: 2022-02-23 (Crawled : 18:00) - biospace.com/
MYMD | $2.5 11.11% 10.0% 54K

Manufacturing

| -45.26% | O: 0.49% H: 2.91% C: -9.93%
health phase 2 als trial therapy enroll

Veru/Lilly Aim to Fill Gap in Second-Line Metastatic Breast Cancer Therapy
Published: 2022-02-23 (Crawled : 14:00) - biospace.com/
VERU | $1.42 22.41% 18.31% 7M

Health Technology

| -73.8% | O: 2.12% H: 1.54% C: -3.88%
therapy cancer breast cancer metastatic breast cancer

Cytokinetics Announces Start of SEQUOIA-HCM, a Phase 3 Clinical Trial of Aficamten in Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Published: 2022-02-23 (Crawled : 13:30) - biospace.com/
CYTK | $67.0 -1.37% -1.39% 890K

Health Technology

| 104.81% | O: 0.0% H: 1.25% C: -6.95%
cardio trial star phase 3

Industry Leaders to Come Together to Advance Digital Trials at Veeva TMF Innovation Forum
Published: 2022-02-23 (Crawled : 12:30) - prnewswire.com
VEEV | News | $199.54 0.17% -0.27% 850K

Technology Services

| -8.52% | O: 0.77% H: 0.2% C: -4.42%
als trials trial

Otis to Attend Barclays Industrial Select Conference
Published: 2022-02-23 (Crawled : 12:30) - prnewswire.com
OTIS | $95.49 0.56% 0.0% 1.8M

Producer Manufacturing

| 24.46% | O: 0.62% H: 0.04% C: -2.71%
trial conference

Kodiak Sciences Announces Top-Line Results from its initial Phase 2b/3 Study of KSI-301 in Patients with Neovascular (Wet) Age-Related Macular Degeneration
Published: 2022-02-23 (Crawled : 12:00) - biospace.com/
KOD | $3.475 -3.47% -3.6% 570K

Health Technology

| -92.85% | O: -78.31% H: 4.76% C: -9.71%
ksi-301 phase 2 phase 2b results macular topline

Follow Live Today: CNH Industrial Capital Markets Day
Published: 2022-02-22 (Crawled : 00:00) - globenewswire.com
CNHI | News | $12.4 0.32% 1.13% 6.1M

Producer Manufacturing

| -21.07% | O: -3.95% H: 2.88% C: -1.13%
day trial oda

CNH Industrial Ventures established to accelerate new technology adoption and nurture disruptive innovation
Published: 2022-02-22 (Crawled : 00:00) - globenewswire.com
CNHI | News | $12.4 0.32% 1.13% 6.1M

Producer Manufacturing

| -21.07% | O: -3.95% H: 2.88% C: -1.13%
technology trial cel new technology

Marinus Pharmaceuticals Announces Delay to RAISE Phase 3 Clinical Trial in Status Epilepticus and Associated IV Ganaxolone Clinical Trials
Published: 2022-02-22 (Crawled : 00:00) - biospace.com/
MRNS | $1.41 -2.08% -2.13% 4.8M

Health Technology

| -87.41% | O: -1.16% H: 2.26% C: 0.99%
epilepticus als trials trial one clinical trials phase 3

Gates Industrial to Host Investor Day
Published: 2022-02-22 (Crawled : 22:00) - prnewswire.com
GTES | $17.18 -0.52% 0.0% 1M

Producer Manufacturing

| 13.25% | O: 0.85% H: 1.27% C: 0.72%
day trial

CNH Industrial presents updated 2024 Strategic Business Plan
Published: 2022-02-22 (Crawled : 22:00) - globenewswire.com
CNHI | News | $12.4 0.32% 1.13% 6.1M

Producer Manufacturing

| -16.89% | O: -2.21% H: 1.58% C: -2.19%
trial